Warum Bitcoin als Wertspeicher in keinem diversifizierten Portfolio fehlen sollte. Jetzt lesen -w-
30.08.2016 22:05:22

Prothena to Participate in Upcoming September Investor Conferences

DUBLIN, Ireland, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in several upcoming investor conferences: 

  • Credit Suisse Antibody Day on September 7, 2016 at 12:00 PM ET in New York, NY
  • Citi's 11th Annual Biotech Conference on September 8, 2016 in Boston, MA
  • Morgan Stanley Global Healthcare Conference on September 12, 2016 at 8:45 AM ET in New York, NY
  • The Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016 at 10:00 AM ET in New York, NY

A live webcast of the company presentations can be accessed under the Investors tab in the Events and Presentations section of the Company's website at www.prothena.com. Following the live presentations, a replay of each webcast will be available on the Company's website for at least 90 days following the presentation date.

About Prothena

Prothena Corporation plc is a global, late-stage clinical biotechnology company seeking to fundamentally change the course of progressive diseases with its clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion - the root causes of many serious or currently untreatable amyloid and inflammatory diseases - Prothena has advanced several drug candidates into clinical trials while pursuing discovery of additional novel therapies.  Our pipeline of antibody-based product candidates targets a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002) and inflammatory diseases, including psoriasis (PRX003), and ATTR amyloidosis (PRX004). For more information, please visit the company's web site at www.prothena.com

For more information, please visit the company's web site at www.prothena.com

Contacts

Investors: Tran Nguyen, CFO
650-837-8535, IR@prothena.com 

Media: Ellen Rose
650-922-2405, ellen.rose@prothena.com 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Prothena Corporation plc via Globenewswire

Analysen zu Prothena Corporation PLCmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Prothena Corporation PLC 14,80 3,50% Prothena Corporation PLC